CE InformationDownload MaterialsCourse Progress
  • Access Webinar
  • Evaluation
  • Certificate
Evaluation

Exploring Current and Emerging Biosimilars for IBD Management

Evaluation

HMP Education would appreciate your feedback on the quality and impact of this activity.

Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little).

To what extent are you able to better achieve each of the following learning objectives?

Describe the role of biosimilars in IBD treatment and their potential to improve access and reduce healthcare costs
Assess common misconceptions regarding the biosimilar development and approval process
Evaluate recent safety and efficacy data associated with current and emerging biosimilars, including both intravenous and subcutaneous formulations
Outline strategies for biosimilar use in clinical practice where appropriate, including clinician and patient education and addressing barriers to patient access to biosimilar IBD care

Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor).

Christina Ha, MD, FACG
David Choi, PharmD
Florian Rieder, MD

Please rate the following components relating to this activity:

Content
Relevance to your practice 
Educational format 
Audience-participation portions (eg., Q&A, polling, pre/post-testing) 
Resources and/or other materials supporting the activity
Overall

Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices.
How many patients do you encounter with IBD on a weekly basis?

Do you feel like there were any new data presented?

Did you learn anything new?

Did you gain confidence on the new information?

Did this program include opportunities to learn as a part of a healthcare team?
According to a recent report, the availability and use of biosimilar medicines has the potential to reduce drug costs by ________ over the next 5 years.
The adalimumab biosimilar, adalimumab-aacf, was approved for the treatment of IBD, in part, based on ________ that demonstrated no clinically significant difference between the biologic and biosimilar.
_________ is the first IBD-indicated FDA-approved interchangeable biosimilar product for its reference product.
Biosimilars are positioned the same as the reference product in the clinical care paradigm and switching may be driven by:
How confident are you now in your ability to appropriately evaluate and utilize biosimilars in clinical practice for the treatment of IBD?

Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific.
What challenges or barriers outside of your control may prevent you from changing your practice?
255 characters max

The information presented in this activity did not serve to advance a proprietary interest of any commercial entity.
Based on my participation in this activity, I anticipate I will more often (select all that apply):